Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Vaxneuvance Market Value Analysis: What Growth Is Expected Over The Forecast Period?
The expansion of routine pneumococcal vaccination programs, coupled with a growing prevalence of pneumococcal infections, has driven historical growth. This was further supported by heightened public awareness of vaccine-preventable diseases, scientific progress in conjugate vaccine development, and better access to healthcare services.
Expansion of national immunization programs, alongside rising investments in next-generation vaccines, a heightened focus on elderly immunization, growing demand for higher-valency vaccines, and increasing adoption in emerging healthcare systems, are driving growth in the forecast period. Key trends include broader adoption of broad-spectrum pneumococcal vaccines, a stronger emphasis on preventing invasive diseases, expanding immunization coverage for both pediatric and adult populations, the advancement of conjugate vaccine technologies, and an enhanced focus on protecting high-risk groups.
Download A Free Sample Report For Comprehensive Market Insights:
Vaxneuvance Market Growth Factors Supporting Long-Term Expansion
The rising occurrence of pneumonia is anticipated to fuel expansion in the vaxneuvance market moving forward. Pneumonia is an infection marked by inflammation in the air sacs of one or both lungs, where they become filled with fluid or pus, leading to signs like cough, fever, and difficulty breathing. This condition is influenced by elements such as viral and bacterial infections, compromised immune systems, air contamination, and a growing elderly population that heightens vulnerability to respiratory illnesses. Vaxneuvance aids patients by offering protection against pneumonia triggered by 15 types of Streptococcus pneumoniae, thereby lowering the chance of serious infections and their associated issues. As an example, data from the Johns Hopkins University, a research institution based in the United States, shows that in 2024, the average Pneumonia GAPPD (Global Action Plan for Pneumonia and Diarrhea) score across 15 nations reached 56%, representing a 2% rise from 54% in 2023. Consequently, the significant rate of pneumonia is propelling the vaxneuvance market forward.
The expansion of vaxneuvance market growth is being propelled by increasing investments in research and development. These investments are on the rise due to a heightened demand for innovation and the necessity to tackle intricate worldwide issues like healthcare, sustainability, and digital transformation. Such growing R&D funding benefits Vaxneuvance by improving its vaccine technology and broadening its capacity to address changing healthcare demands. To illustrate, the Office for National Statistics (ONS), a UK-based entity that produces official data, reported in April 2025 that the UK government’s net R&D expenditure climbed by 8.2% year-over-year, going from $19.9 billion in 2022 to $21.5 billion in 2023. Thus, the uptick in research and development investments is fostering the growth of the vaxneuvance market.
Vaxneuvance Market Segment Performance And Strategic Opportunities
The vaxneuvance market covered in this report is segmented –
1) By Indication: Pneumonia, Meningitis, Sepsis, Bacteremia, Otitis Media
2) By Distribution Channel: Pharmacies, Hospitals
3) By End User: Adults, Children, Geriatric Population
Vaxneuvance Market Industry Trends Shaping Future Revenue Growth
Major players in the vaxneuvance market, which is a pneumococcal conjugate vaccine, are concentrating their efforts on developing new solutions, especially next-generation multivalent conjugate vaccines, with the aim of delivering more comprehensive protection against pneumococcal infections. These next-generation multivalent conjugate vaccines represent an advanced type of immunization, engineered to fight multiple pathogen strains by attaching polysaccharides from each strain to a carrier protein, thereby boosting the immune response. As an example, in May 2025, Vietnam Vaccine JSC (VNVC), headquartered in the United States, launched the pneumococcal 15-valent conjugate vaccine, also known as PCV15 or Vaxneuvance, which increases defense against various strains of Streptococcus pneumoniae that cause both invasive and non-invasive illnesses. This vaccine is indicated for children starting at six weeks of age and for adults, ensuring sustained immunity and helping to curb the spread of pneumococcal bacteria within communities. With this introduction, VNVC takes a leading role in modern pneumococcal vaccination efforts in Vietnam, enhancing its current lineup of pneumococcal vaccines and supporting nationwide immunization programs.
Vaxneuvance Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the vaxneuvance market are Merck & Co. Inc.
Access The Complete Vaxneuvance Market Report:
Vaxneuvance Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the vaxneuvance market in 2025. The regions covered in the vaxneuvance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model